BRISTOL MYERS SQUIBB

🇫🇷France

Country: 🇫🇷France

Ownership: -

Established: 1989-01-01

Employees: 30K

Market Cap: $97.5B

Website: https://www.bms.com/

Clinical Trials

Long-term Epidemiological Follow-up of Non-small Cell Lung Cancer in Scandinavia

Completed

Conditions: Non-Small Cell Lung Cancer

First Posted Date: 2016-07-21

Last Posted Date: 2022-02-24

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 5657

Registration Number: NCT02839629

ELIQUIS (APIXABAN) Regulatory Post-Marketing Surveillance In Clinical Practice for Venous Thromboembolism (VTE) Treatment and Prevention Of Recurrent VTE

Completed

Conditions: Venous Thromboembolism

First Posted Date: 2016-07-19

Last Posted Date: 2022-02-21

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 1134

Registration Number: NCT02836457

Locations: 🇯🇵
Local Institution, Shinjuku-ku, Tokyo, Japan

An Open Label Investigational Immuno-therapy Trial of Nivolumab in Cancers That Are Advanced or Have Spread

Phase 2

Completed

Conditions: Cancer

Interventions: Biological: Nivolumab

First Posted Date: 2016-07-14

Last Posted Date: 2022-05-09

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 239

Registration Number: NCT02832167

Locations: 🇺🇸
Cancer Center of Santa Barbara with Sansum Clinic, Santa Barbara, California, United States
🇺🇸
Memorial Healthcare System, Hollywood, Florida, United States
🇺🇸
Florida Cancer Specialists, West Palm Beach, Florida, United States

and more 37 locations

The Effect of BMS-986142 on the Pharmacokinetics of a Combined Oral Contraceptive (OC) Containing Ethinyl Estradiol (EE) and Norethindrone Acetate (NET) in Healthy Female Subjects

Phase 1

Completed

Conditions: Arthritis

Interventions: Drug: OC containing EE and NET
Drug: BMS-986142

First Posted Date: 2016-07-14

Last Posted Date: 2016-12-26

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 25

Registration Number: NCT02832180

Locations: 🇺🇸
Covance Evansville Clinical Research Unit, Evansville, Indiana, United States
🇺🇸
Miami Research Associates, Miami, Florida, United States

A Study of the Safety and Tolerability of BMS-986183 in Patients With Liver Cancer

Phase 1

Terminated

Conditions: Hepatocellular Carcinoma

Interventions: Biological: BMS-986183
Biological: Nivolumab

First Posted Date: 2016-07-11

Last Posted Date: 2019-01-30

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 25

Registration Number: NCT02828124

Locations: 🇨🇳
Local Institution, Taipei, Taiwan

Study of Nivolumab in Combination With Ipilimumab Versus Nivolumab in Combination With Ipilimumab Placebo in Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck

Phase 2

Completed

Conditions: Head and Neck Cancer

Interventions: Biological: Nivolumab
Biological: Ipilimumab
Other: Placebo

First Posted Date: 2016-07-06

Last Posted Date: 2023-05-03

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 425

Registration Number: NCT02823574

Locations: 🇺🇸
Local Institution - 0087, Chicago, Illinois, United States
🇨🇦
Local Institution - 0014, Quebec, Canada
🇧🇪
Local Institution - 0023, Gent, Belgium

and more 98 locations

A First-in-Human Study of the Safety of Single Continuous Intravenous (IV) Infusions of CXL-1427 for up to 48 Hours in Healthy Volunteers

Phase 1

Completed

Conditions: Heart Failure

Interventions: Drug: CXL-1427 Ascending Dose
Other: Placebo
Drug: CXL-1427 Descending Dose

First Posted Date: 2016-06-30

Last Posted Date: 2017-01-23

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 80

Registration Number: NCT02819271

Trial of BMS-986012 in Combination With Platinum and Etoposide

Phase 1

Active, not recruiting

Conditions: Small Cell Lung Cancer

Interventions: Drug: BMS-986012
Drug: Etoposide
Drug: Cisplatin
Drug: Platinum
Drug: Carboplatin

First Posted Date: 2016-06-28

Last Posted Date: 2024-05-23

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 12

Registration Number: NCT02815592

Locations: 🇪🇸
Local Institution - 0002, Barcelona, Spain
🇪🇸
Local Institution - 0004, Madrid, Spain
🇪🇸
Local Institution - 0010, Malaga, Spain

and more 1 locations

A Study to Evaluate the Effect of Co-administration of Itraconazole or Diltiazem on the Pharmacokinetics of BMS-986177 in Healthy Subjects

Phase 1

Completed

Conditions: Thrombosis

Interventions: Drug: BMS-986177
Drug: Itraconazole
Drug: Diltiazem ER

First Posted Date: 2016-06-21

Last Posted Date: 2016-09-12

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 28

Registration Number: NCT02807909

Interferon Toxicities in Melanoma Treatment

Completed

Conditions: Stage III Melanoma

First Posted Date: 2016-06-09

Last Posted Date: 2016-06-09

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 436

Registration Number: NCT02794636

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy